Novo Nordisk expresses optimism on diabetes drug

11/16/2007 | Reuters

Novo Nordisk expressed confidence that its Type 2 diabetes drug liraglutide is as effective as Eli Lilly & Co.'s Byetta drug in treating the disease. The company is planning to bolster its U.S. sales force to promote its drug to general practitioners -- a move that could give the firm a competitive advantage over a long-acting version of Byetta, a Novo Nordisk official said at a health summit.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ